CLINICAL PHASE I TRIAL WITH HEPATITIS C VIRUS PROTEASE INHIBITOR INITIATED
Medivir, on behalf of the Tibotec and Medivir collaborative project, announced that this week Tibotec initiated a phase I clinical trial with a potent and selective hepatitis C virus (HCV) NS3/4A protease inhibitor, for the treatment of chronic hepatitis C virus infection. The phase Ia clinical trial is designed to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. The study will be conducted in Europe.The preclinical research conducted on the clinical candidate demonstrated favorable characteristics in potency, cross-resistance profiles and pharmacokinetic